NASDAQ: ZVSAZyversa Therapeutics Inc Stock
$0.63+0.05 (+8.62%)
Updated Apr 18, 2024
ZVSA Price
$0.63
Fair Value Price
N/A
Market Cap
$4.75M
52 Week Low
$0.50
52 Week High
$90.65
P/E
-0.01x
P/B
0.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$98.30M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1
Operating Cash Flow
-$9M
Beta
0.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ZVSA Overview
Larkspur Health Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the biotech sector in the U.S. Larkspur Health Acquisition was incorporated in 2021 and is headquartered in Bridgewater, NJ.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ZVSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZVSA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZVSA is good value based on its book value relative to its share price (0.43x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
ZVSA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ZVSA due diligence checks available for Premium users.
Be the first to know about important ZVSA news, forecast changes, insider trades & much more!
ZVSA News
Valuation
ZVSA fair value
Fair Value of ZVSA stock based on Discounted Cash Flow (DCF)
Price
$0.63
Fair Value
$0.64
Undervalued by
1.96%
ZVSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ZVSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
15.68x
Market
41.33x
ZVSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.43x
Industry
5.76x
ZVSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZVSA's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.3M
Profit Margin
0%
ZVSA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$22.1M
Liabilities
$11.0M
Debt to equity
1
ZVSA's short-term liabilities ($10.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZVSA's short-term assets ($3.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZVSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
$0.0
Financing
$4.3M
ZVSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZVSA vs Biotech Stocks
Zyversa Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.